Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

183
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
183
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

159
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
159
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transferrin in combination with induction chemotherapy improves outcomes in mouse models of acute myeloid leukemia.

Science translational medicine·2026
Same author

The toxic effect of glycerol-Cu(II) counterions on the free-living stages of Aedes aegypti.

Anais da Academia Brasileira de Ciencias·2025
Same author

Correction: Amaral et al. Thermochemical Research on Furfurylamine and 5-Methylfurfurylamine: Experimental and Computational Insights. <i>Molecules</i> 2024, <i>29</i>, 2729.

Molecules (Basel, Switzerland)·2025
Same author

New Conjugatable Platinum(II) Chlorins: Synthesis, Reactivity and Singlet Oxygen Generation.

Molecules (Basel, Switzerland)·2025
Same author

Exploring the Interaction of 3-Hydroxy-4-pyridinone Chelators with Liposome Membrane Models: Insights from DSC and EPR Analysis.

Molecules (Basel, Switzerland)·2025
Same author

Impact of Fe<sup>3+</sup>/Polyphenol Ratio in Iron-gall Ink on Superoxide Formation: Rationalizing Historic Recipes from a Kinetic Study.

Chemphyschem : a European journal of chemical physics and physical chemistry·2024

Related Experiment Video

Updated: Jul 11, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.6K

Vanadium Compounds with Antidiabetic Potential.

Luísa M P F Amaral1, Tânia Moniz1,2, André M N Silva1,2

  • 1LAQV, REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, s/n, 40169-007 Porto, Portugal.

International Journal of Molecular Sciences
|November 14, 2023
PubMed
Summary
This summary is machine-generated.

Vanadium compounds show promise for diabetes treatment, acting similarly to insulin. Further research is needed to fully understand their mechanisms and develop effective therapies for metabolic control.

Keywords:
antidiabetic drugschemical speciationdiabetes mellitusinsulin signalingmetallopharmaceuticalsvanadiumvanadium complexes

More Related Videos

Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.0K

Related Experiment Videos

Last Updated: Jul 11, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.6K
Homogeneous Time-resolved F&#246;rster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.0K

Area of Science:

  • Medicinal Chemistry
  • Biochemistry
  • Pharmacology

Background:

  • Vanadium compounds have been investigated for antidiabetic properties for over 40 years.
  • Their chemical structure and similarity to phosphate are key to their biological activity.

Purpose of the Study:

  • To review promising vanadium compounds for diabetes treatment.
  • To summarize in vivo studies and clinical trials from 1899-2023.
  • To explore mechanisms of action and future research directions.

Main Methods:

  • Literature review of studies on vanadium compounds and diabetes.
  • Analysis of chemical structure, biochemistry, and spectroscopic characterization.
  • Summary of in vivo (animal models) and human clinical trial data.

Main Results:

  • Vanadate's chemical properties, particularly its phosphate mimicry, are crucial for its antidiabetic effect.
  • Spectroscopic methods aid in understanding vanadium compound activity and interactions.
  • Studies show potential in animal models and human trials, though mechanisms require further elucidation.

Conclusions:

  • Vanadium compounds offer potential for diabetes management as insulin-like agents or adjuvants.
  • Further research is essential to fully understand their pharmacological actions and optimize therapeutic use.
  • Continued investigation may lead to novel vanadium-based antidiabetic drugs.